StockNews.AI
BTAI
StockNews.AI
172 days

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

1. BioXcel Therapeutics regained Nasdaq compliance regarding bid price requirement. 2. The compliance issue arose from a drop below $1.00 per share for 30 days. 3. The company maintained the minimum bid price for 12 consecutive days recently. 4. BTAI utilizes AI for drug development in neuroscience and immuno-oncology. 5. The company’s AI approach may enhance market confidence moving forward.

3m saved
Insight
Article

FAQ

Why Bullish?

Regaining compliance often stabilizes stock performance, as seen with other companies. This suggests renewed investor confidence and potential price support.

How important is it?

Gaining compliance is crucial for market perception, influencing investor trust and trading activity.

Why Short Term?

Immediate positive market response is likely, but longer-term stability depends on ongoing performance. Previous compliance resolutions have led to short-term price improvements.

Related Companies

JNJPFEABBV
February 28, 2025 07:00 ET  | Source: BioXcel Therapeutics NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on September 16, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days. This requirement was met on February 26, 2025. About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com. Contact Information Corporate/InvestorsBioXcel Therapeutics Erik Kopp 1.203.494.7062 MediaRusso PartnersDavid Schull 1.858.717.2310 Source: BioXcel Therapeutics, Inc.

Related News